APOLLO Dream® Sirolimus Target Eluting Stent System Granted FDA Breakthrough Device Designation
Shanghai, China – March 29, 2026 – Recently, The board of directors (the “Board”) of MicroPort NeuroScientific Corporation (the “Company”, 2172.HK, together with its subsidiaries, the “Group”) is pleased to announce that APOLLO Dream® Sirolimus Target Eluting Stent System (“APOLLO Dream®”) has been granted the Breakthrough Device Designation by the U.S. Food and Drug Administration (“FDA”).
